Benchling

What are the biggest themes from AALAS 2024? In vivo research practices are quickly changing, with digitization enabling rapid, high-volume data capture and reshaping the way animal studies are run. Here are top trends we heard: ✨ Eliminate silos of data and errors ✨ Digitize lab processes — no more paper! ✨ Build the highest level of animal welfare practices into lab workflows Get the recap: https://lnkd.in/eNpKC2pR

I know, I know, I know! It is old news but I'm still super proud of this picture 😍 Thanks for the warm welcome to the Benchling family and especially Ashu and Sajith for believing in what our companies can do together in #antibody drug discovery, #bioinformatics, #AI and a lot more 🙏

🎁 What do you give a jellyfish for the holidays? This year, #JeffyP’s been browsing our users’ top requested product features, and now all he wants is: 1️⃣ Bulk update tool for Results tables 2️⃣ Self-serve computed registry fields 3️⃣ API control of schema creation and updates 4️⃣ Schema fieldsets for flexible entity linking Join JeffyP and over 1800 Benchling users in our online #Community to submit and upvote product ideas! https://lnkd.in/eHD6JuZZ ⛄ Want to win a Benchling holiday sweater? Like, share, or comment on our #12DaysOfBenchling posts! Contest rules: https://lnkd.in/e_cvkh7W

🎵 On the 2nd of December, #JeffyP gave to me, a special Benchling sweater for free! 🎁 ‘Tis the season for gift giving, so to get you in the spirit (and have something to wear to your lab holiday party), we’re kicking off our first-ever #12DaysOfBenchling and we’d love for you to join the fun! For the next 12 days, JeffyP will be sharing his favorite moments of 2024 — and looking ahead to the new year. Like, share, or comment on our #12DaysOfBenchling posts for a chance to win one of 12 limited edition holiday sweaters! ⛄ Contest rules: https://lnkd.in/e_cvkh7W

That feeling when people come to your events... wearing your swag. 🧦💕

🇫🇷 Scenes from the French #biotech community: Yesterday, over 100 scientists, developers, and innovators came together to share ideas, make new connections, and discuss strategies for modernizing — and importantly, accelerating — their R&D. It was inspiring to see everyone — across #biopharma, biomaterials, future foods, and more — coming together with such enthusiasm. What was even more powerful was the eagerness to exchange insights and advance digital transformation as a community. Key topics included #AI-reinforced antibody discovery, automated data management, and API-driven infrastructure 👏 Thanks to everyone who joined us for Digital Science & Innovation Day in Paris! Special thanks to our amazing speakers: Elodie Pronier (Owkin) Jean-Louis Honeine (Benchling) Johanna Michielin (BioLabs) Maya Bendifallah, PhD (Nutropy) Meritxell Orpinell, PhD, PMP (Benchling) Patrick Torbey (Neoplants) peggy willemarck (Sanofi) Pierre Salvy (Cambrium) Radoslaw Ejsmont (SYNOVANCE) Sylvain Yon (Mabqi) Suchitra Ramaswamy (Zifo)

"One of the major challenges we are tackling [in adopting AI] is modernizing our legacy systems and stitching together data that is coming from a lot of different places," said Will Weiss, AVP Biotechnology Discovery Research at Eli Lilly and Company. Much of #biopharma is still struggling with this — 43% of large biopharma #IT support 20+ different scientific software applications, many of which are custom-built.   Learn about the tech strategies that large and small biopharma are adopting to pave the way for #AI readiness: https://lnkd.in/evS3D4XS

Benchling’s State of Tech in Biopharm Part 2: David vs Goliath This year’s report focused mainly on the differences between big and small biopharm companies adoption/deployment of various technologies. As someone who has spent the last 6+ years in small biotechs (and the previous 6+ years at a fortune 50), many of these findings rang true. Small companies have significantly different priorities and resources, especially in the post-Covid biotech environment. The report found these differences were most drastic in AI/ML deployment and Lab Automation. In the lab automation space, deployment at a small biotech can be difficult. Capital is often tighter, timelines more urgent, and the science can be less established. I have been fortunate to be at biotechs where lab automation has been a core strategy and priority, but the report shows that is not the case for 73% of small biotechs. I keep thinking that cloud labs/hybrid cloud labs will one day fill this gap. There has to be a way for early stage companies to establish the cultural and scientific benefits of lab automation without taking on all the capital investment and timeline risks. One of these days it will happen!

How do you move drug candidates through the pipeline faster? SNIPR Biome - A CRISPR Company is pioneering the discovery and development of #CRISPR-based microbiome drugs — with all their R&D data on a single end-to-end platform. We’re proud to have served SNIPR Biome from nearly the beginning. See why building a strong data foundation accelerates time to milestone: https://lnkd.in/etU6PapW #BuiltOnBenchling

I got 96 problems, but a map ain’t one. Plate maps are here! 👉 Find out how to visualize and annotate wells in Benchling, using an easy, intuitive interface: https://lnkd.in/ghKAxBDJ 👀 See what else is new: https://lnkd.in/eQecRPSR #FeatureFriday